High-dose ruxolitinib and stem cell transplant for enlarged spleen in myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have myelofibrosis (either primary or secondary), and you may have already taken ruxolitinib or similar drugs.
- You have an enlarged spleen (felt by your doctor or seen on a scan).
- You have a fully matched donor (a related or unrelated donor who matches at 8 out of 8 key markers).
- Your kidneys and liver are working well enough (based on blood tests).
- You are not pregnant and agree to use effective birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This Phase 1 study tests CK0804 (plus T-regs, a type of immune cell approach) for people with myelofibrosis whose disease is not adequately controlled on ruxolitinib. It may help improve blood counts, symptoms, and/or the size of an enlarged spleen.
This trial tests a new drug called RVU120 for people with myelofibrosis that has not responded well to standard JAK inhibitor treatment. It aims to shrink the spleen and improve symptoms.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
Hear when a new Splenomegaly trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.